Gene
XRCC3
X-ray repair cross complementing 3
Explore in graph →CI-GENE-00039006HGNC:12830 ENSG00000126215 NCBI 7517 CIViC Approved
Curated evidence
Clinical evidence (1)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37029129
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ORC1 Mutation + XRCC3 MutationXRCC3ORC11 | ||||||||
| Cisplatin | Triple-Negative Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11716In this study, the sensitivity to Cisplatin (a platinum-based drug) was studied in XRCC3 knockout, and ORC1 mutant PDX models. A role of XRCC3 loss in cisplatin sensitivity was reported in the study. … (full text at CIViC) PMID 37029129 · Ter Brugge et al., 2023 · Open in CIViC | civic |
Cohorts
Alteration frequency by cohort (0)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
Data not yet available
No cohort frequency recorded for this gene.
Literature
Linked publications (0)
Data not yet available
No publication linked to this gene yet.